Eli Lily has made a bold move to expand access to its weight loss drug Zep Bound by offering it at half the usual price the new single dose vials are priced at 3899 for 2.5 migon and $549 for 5 migon compared to the typical $1,000 monthly cost this aims to make the drug more accessible to uninsured patients and those on Medicare by selling through its direct to Consumer platform Lily direct Eli Lily cuts out supply chain markups making the drug more affordable the switch to single dose files also boosts production addressing Supply constraints and countering the rise of unapproved copycat versions Eli Lily's efforts extend to safeguarding patient safety by suing those selling unauthorized versions this move challenges outdated Health Care policies that don't cover obesity drugs pushing for change in how obesity is treated Eli Lily's strategy is setting a new standard in patient care and access reshaping the health care landscape